Universal Beteiligungs und Servicegesellschaft mbH Has $12.56 Million Stock Position in United Therapeutics Corporation $UTHR

Universal Beteiligungs und Servicegesellschaft mbH lessened its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 6.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,694 shares of the biotechnology company's stock after selling 2,996 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.10% of United Therapeutics worth $12,555,000 at the end of the most recent reporting period.The Top 3 Stock Picks at the World’s Greatest Hedge FundOther large investors have also recently bought and sold shares of the company. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $29,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at $32,000. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group boosted its stake in shares of United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 98 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of United Therapeutics during the 1st quarter valued at approximately $60,000. 94.08% of the stock is currently owned by institutional investors and hedge funds. Get United Therapeutics alerts:United Therapeutics Stock PerformanceNASDAQ:UTHR opened at $476.54 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $485.32. The firm's fifty day moving average is $436.99 and its 200-day moving average is $353.41. The firm has a market cap of $20.52 billion, a P/E ratio of 18.06, a P/E/G ratio of 4.96 and a beta of 0.77. Liquidia: Court victory the awakening of an industry giant?United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts' consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business's revenue was up 6.8% compared to the same quarter last year. During the same period last year, the business posted $6.39 EPS. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year. Analysts Set New Price TargetsUTHR has been the topic of a number of research analyst reports. Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Weiss Ratings reiterated a "buy (b-)" rating on shares of United Therapeutics in a research report on Thursday, November 13th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 30th. HC Wainwright upped their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a "buy" rating in a research report on Thursday, October 30th. Finally, Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a report on Friday, September 5th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $505.00.Analysts Say These 2 Mid-Cap Biotechs Have 2x PotentialView Our Latest Stock Report on UTHRInsider Transactions at United TherapeuticsIn other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold 511,935 shares of company stock valued at $221,082,497 over the last quarter. 10.30% of the stock is currently owned by insiders. United Therapeutics Company Profile (Free Report)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.Featured StoriesFive stocks we like better than United TherapeuticsThe 3 Best Blue-Chip Stocks to Buy Nowonsemi Places a $6 Billion Bet on Its Own StockRussell 2000 Index, How Investors Use it For Profitable TradingHIMS Has Been a Roller Coaster Ride. Should Investors Hop On?What is a Dividend King? End the Year Strong With These 3 Comeback ChampionsWant to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in United Therapeutics Right Now?Before you consider United Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here